Antifungal susceptibilities of clinical isolates of Candida species, Cryptococcus neoformans, and Aspergillus species from Taiwan:: Surveillance of multicenter antimicrobial resistance in Taiwan program data from 2003

被引:73
作者
Hsueh, PR
Lau, YJ
Chuang, YC
Wan, JH
Huang, WK
Shyr, JM
Yan, JJ
Yu, KW
Wu, JJ
Ko, WC
Yang, YC
Liu, YC
Teng, LJ
Liu, CY
Luh, KT
机构
[1] Natl Taiwan Univ, Natl Taiwan Univ Hosp, Coll Med, Dept Lab Med, Taipei 100, Taiwan
[2] Natl Taiwan Univ, Natl Taiwan Univ Hosp, Coll Med, Dept Internal Med, Taipei 100, Taiwan
[3] Taipei Vet Gen Hosp, Taipei, Taiwan
[4] Taichung Vet Gen Hosp, Taichung, Taiwan
[5] China Med Coll Hosp, Taichung, Taiwan
[6] Chi Mei Med Ctr, Tainan, Taiwan
[7] Natl Cheng Kung Univ Hosp, Tainan 70428, Taiwan
[8] Kaohsiung Vet Gen Hosp, Kaohsiung, Taiwan
关键词
D O I
10.1128/AAC.49.2.512-517.2005
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
The susceptibilities of nonduplicate isolates to six antifungal agents were determined for 391 blood isolates of seven Candida species, 70 clinical isolates (from blood or cerebrospinal fluid) of Cryptococcus neoformans, and 96 clinical isolates of four Aspergillus species, which were collected in seven different hospitals in Taiwan (as part of the 2003 program of the study group Surveillance of Multicenter Antimicrobial Resistance in Taiwan). All isolates of Candida species other than C glabrata and C krusei were susceptible to fluconazole. Among the 59 C glabrata isolates, 16 (27%) were not susceptible to fluconazole, and all were dose-dependently susceptible or resistant to itraconazole. For three (5.1%) C glabrata isolates, voriconazole MICs were 2 to 4 mug/ml, and for all other Candida species isolates, voriconazole MICs were less than or equal to0.5 mug/ml. The proportions of isolates for which amphotericin B MICs were greater than or equal to2 mug/ml were 100% (3 isolates) for C. krusei, 11% (23 of 207 isolates) for Candida albicans, 3.0% (2 of 67 isolates) for Candida tropicalis, 20% (12 of 59 isolates) for C. glabrata, and 0% for both Candida parapsilosis and Candida lusitaniae. For three (4%) Cryptococcus neoformans isolates, fluconazole MICs were greater than or equal to16 mug/ml, and two (3%) isolates were not inhibited by 1 mug of amphotericin B/ml. For four (4.2%) of the Aspergillus isolates, itraconazole MICs were 8 mug/ml. Aspergillus flavus was less susceptible to amphotericin B, with the MICs at which 50% (1 mug/ml) and 90% (2 mug/ml) nsrsid417869\delsrid7301351 of isolates were inhibited being twofold greater than those for Aspergillus fumigatus and Aspergillus niger. All Aspergillus isolates were inhibited by less than or equal to1 mug of voriconazole/ml, including isolates with increased resistance to amphotericin B and itraconazole. This study revealed the emergence in Taiwan of decreased susceptibilities of Candida species to amphotericin B and of C. neoformans to fluconazole and amphotericin B. Voriconazole was the most potent agent against the fungal isolates tested, including fluconazole- and amphotericin B-nonsusceptible strains.
引用
收藏
页码:512 / 517
页数:6
相关论文
共 38 条
[1]   In vitro susceptibilities of Aspergillus species to voriconazole, itraconazole, and amphotericin B [J].
Abraham, OC ;
Manavathu, EK ;
Cutright, JL ;
Chandrasekar, PH .
DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE, 1999, 33 (01) :7-11
[2]   Correlation of fluconazole MICs with clinical outcome in Cryptococcal infection [J].
Aller, AI ;
Martin-Mazuelos, E ;
Lozano, F ;
Gomez-Mateos, J ;
Steele-Moore, L ;
Holloway, WJ ;
Gutiérrez, MJ ;
Recio, FJ ;
Espinel-Ingroff, A .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2000, 44 (06) :1544-1548
[3]   Microdilution susceptibility testing of amphotericin B, itraconazole, and voriconazole against clinical isolates of Aspergillus and Fusarium species [J].
Arikan, S ;
Lozano-Chiu, M ;
Paetznick, V ;
Nangia, S ;
Rex, JH .
JOURNAL OF CLINICAL MICROBIOLOGY, 1999, 37 (12) :3946-3951
[4]   Aspergillus fumigatus variant with decreased susceptibility to multiple antifungals [J].
Balajee, SA ;
Weaver, M ;
Imhof, A ;
Gribskov, J ;
Marr, KA .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2004, 48 (04) :1197-1203
[5]   Trends in antifungal use and epidemiology of nosocomial yeast infections in a university hospital [J].
Berrouane, YF ;
Herwaldt, LA ;
Pfaller, MA .
JOURNAL OF CLINICAL MICROBIOLOGY, 1999, 37 (03) :531-537
[6]   Aspergillus: Rising frequency of clinical isolation and continued susceptibility to antifungal agents, 1994-1999 [J].
Chandrasekar, PH ;
Cutright, JL ;
Manavathu, EK .
DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE, 2001, 41 (04) :211-214
[7]   Pulmonary fungal infection - Emphasis on microbiological spectra, patient outcome, and prognostic factors [J].
Chen, KY ;
Ko, SC ;
Hsuech, PR ;
Luh, KT ;
Yang, PC .
CHEST, 2001, 120 (01) :177-184
[8]   Stable susceptibility of Candida blood isolates to fluconazole despite increasing use during the past 10 years [J].
Chen, YC ;
Chang, SC ;
Luh, KT ;
Hsieh, WC .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2003, 52 (01) :71-77
[9]   Distribution and antifungal susceptibility of Candida species causing candidemia from 1996 to 1999 [J].
Cheng, MF ;
Yu, KW ;
Tang, RB ;
Fan, YH ;
Yang, YL ;
Hsieh, KS ;
Ho, M ;
Lo, HJ .
DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE, 2004, 48 (01) :33-37
[10]   Susceptibility testing of sequential isolates of Aspergillus fumigatus recovered from treated patients [J].
Dannaoui, E ;
Meletiadis, J ;
Tortorano, AM ;
Symoens, F ;
Nolard, N ;
Viviani, MA ;
Piens, MA ;
Lebeau, B ;
Verweij, PE ;
Grillot, R .
JOURNAL OF MEDICAL MICROBIOLOGY, 2004, 53 (02) :129-134